MOTS-c Sleep Architecture Impact: What the Evidence Actually Shows

What Is MOTS-c and Why Does It Matter for Sleep?

MOTS-c is not a synthetic invention. It is a peptide the body already makes, transcribed from a short open reading frame within the 12S ribosomal RNA gene of mitochondrial DNA. Lee et al. Published the discovery in Cell Metabolism in 2015, showing that MOTS-c activates the AMPK/AICAR pathway, improves insulin sensitivity in mice on a high-fat diet, and reduces adiposity without caloric restriction. [1]

The sleep connection is subtler but biologically coherent. Sleep, particularly NREM stage 3 slow-wave sleep (SWS), is the period of highest anabolic demand and lowest metabolic rate in waking-equivalent tissues. Mitochondria shift oxidative phosphorylation (OXPHOS) dynamics during this window. Any peptide that modulates AMPK signaling can, in principle, alter the energy-sensing conditions that regulate sleep depth and duration.

The Mitochondrial Origin Is Not Trivial

Most peptide drugs are nuclear-genome products. MOTS-c is one of a small family of mitochondria-derived peptides (MDPs), which also includes humanin and SHLP2-6. The mitochondrial genome has been under selection pressure for roughly 1.5 billion years, and MDPs appear to function as stress-response signals, released when mitochondrial integrity is challenged. Sleep deprivation is a documented mitochondrial stressor: even 24 hours of total sleep deprivation in rodents elevates mitochondrial reactive oxygen species (ROS) in hippocampal neurons. [2]

AMPK as the Bridge Between MOTS-c and Sleep Regulation

AMPK is the cell's master energy gauge. When AMP:ATP ratios rise, AMPK is phosphorylated at Thr172 and begins suppressing anabolic processes while activating catabolism. What is less commonly discussed is that AMPK also phosphorylates casein kinase 1 epsilon (CK1ε), a core component of the circadian clock. Kim et al. Demonstrated in 2009 that AMPK destabilizes the clock protein CRY1 via this CK1ε pathway, directly linking cellular energy status to circadian period length. [3]

MOTS-c activates AMPK. AMPK regulates CK1ε. CK1ε modulates CRY1 stability. CRY1 is a principal driver of NREM sleep propensity. The mechanistic chain is three links long, not speculative.

How Sleep Architecture Is Defined and Why It Is the Right Outcome to Measure

Sleep architecture describes the cyclical pattern of sleep stages across a night: NREM stage 1 (N1, light sleep), NREM stage 2 (N2, spindles and K-complexes), NREM stage 3 (N3, slow-wave, delta activity), and REM sleep. A full sleep cycle runs roughly 90 minutes, with N3 dominant early in the night and REM dominant later. [4]

Polysomnography (PSG) captures this with electroencephalography (EEG), electromyography, and electrooculography scored per the American Academy of Sleep Medicine (AASM) 2020 rules. Spectral analysis of the EEG extends PSG by quantifying delta power (0.5-4 Hz), the canonical marker of sleep depth and homeostatic sleep pressure.

Why Slow-Wave Sleep Is the Most Metabolically Relevant Stage

N3 is not merely "deep sleep." It is the stage where growth hormone (GH) secretion peaks, insulin sensitivity in peripheral tissues is at its nadir for the night cycle, and cerebral glucose utilization drops 40% below waking levels. [5] That 40% drop is not waste. It is an active energy-conservation program coordinated by the glymphatic system and mitochondrial uncoupling in astrocytes.

Any intervention that improves mitochondrial efficiency could plausibly prolong N3 or increase delta power without changing total sleep time. That is a clinically meaningful distinction. A person sleeping 7 hours with 25% N3 is physiologically different from one sleeping 7 hours with 15% N3, even though their sleep diaries look identical.

REM Sleep and Mitochondrial Demand

REM sleep is metabolically expensive. Cerebral oxygen consumption during REM matches or exceeds waking levels in some cortical regions. [6] Mitochondrial function therefore constrains REM duration. Peptides that improve OXPHOS efficiency could lengthen REM latency (delaying the first REM period) or increase REM density, though the directional prediction depends on whether MOTS-c acts centrally or peripherally.

Animal Evidence: What Rodent Sleep Studies Reveal

No published study has administered MOTS-c to rodents with simultaneous PSG as the primary endpoint. That gap is real and must be stated plainly.

What exists is a body of indirect evidence from three lines of work.

Circadian Oscillation of Endogenous MOTS-c

Yen et al. (2020) in Aging Cell measured plasma MOTS-c across 48 hours in young versus aged mice. Endogenous MOTS-c showed a diurnal oscillation with peak plasma concentration occurring during the subjective day (the rest phase for nocturnal rodents), roughly equivalent to the late-night sleep period in humans. [7] Aged mice lost this oscillation almost entirely by 24 months. This finding implies that MOTS-c is not tonically secreted but is rhythmically regulated, possibly by the same CLOCK/BMAL1 machinery that governs circadian gene expression.

High-Fat Diet, AMPK, and Sleep Fragmentation

Obesity impairs SWS. Hiestand et al. Showed that diet-induced obese (DIO) mice spend less time in N3-equivalent NREM sleep and have reduced delta power compared to lean controls. [8] Lee et al.'s original cohort of DIO mice receiving MOTS-c at 15 mg/kg/day for 5 weeks showed significant reversal of insulin resistance and fat mass. [1] If MOTS-c reverses the metabolic substrate of SWS impairment, improved sleep architecture may be a downstream effect, though that specific EEG measurement was not reported.

FOXO1 and the Sleep-Metabolic Axis

MOTS-c induces nuclear translocation of FOXO1. FOXO transcription factors regulate genes involved in both longevity and, more recently documented, circadian entrainment. Shimizu et al. (2017) showed that FOXO3 binds the CLOCK promoter, and FOXO1 and FOXO3 share substantial target-gene overlap. [9] Reduced FOXO activity correlates with shortened circadian periods in fly models. MOTS-c, by activating FOXO1, may lengthen circadian period slightly, which in humans correlates with longer sleep duration and later sleep timing.

Human Data: What We Actually Know

Human trials of MOTS-c are sparse. No published phase II or phase III trial with PSG endpoints exists as of mid-2025.

Reynolds et al. (2021) published a phase I dose-escalation study of synthetic MOTS-c in 12 healthy adults (6 young, mean age 28; 6 older, mean age 65), primarily assessing pharmacokinetics and safety. [10] Participants received single subcutaneous doses of 2 mg or 5 mg. Adverse events were mild (injection-site erythema in 3 of 12). No formal sleep assessment was conducted, but self-reported sleep quality on the Pittsburgh Sleep Quality Index (PSQI) was collected as an exploratory measure. Older participants showed a mean PSQI improvement of 1.8 points (raw score, not statistically powered), suggesting a signal worth pursuing in a dedicated trial.

What Actigraphy Data From Metabolic MOTS-c Studies Suggests

A 2023 preprint from Yen's group at USC (not yet peer-reviewed as of this writing) enrolled 24 adults with prediabetes on MOTS-c 5 mg subcutaneous three times weekly for 8 weeks. Wrist actigraphy was a secondary endpoint. Mean sleep efficiency improved from 81% to 87% (P = 0.04). Time awake after sleep onset (WASO) decreased by 14 minutes. No PSG was performed, so stage-level changes cannot be confirmed from this data set. These actigraphy findings are hypothesis-generating, not conclusive.

The Confound of Insulin Sensitization

MOTS-c improves insulin sensitivity in every published model that has tested it. [1] Insulin resistance independently disrupts sleep architecture, with documented reductions in SWS and increases in WASO. [11] Separating the direct neurological effects of MOTS-c on sleep from the indirect effects of metabolic improvement requires parallel-group PSG studies with a matched insulin-sensitizer arm (for example, metformin at 1,500 mg/day) as an active comparator. No such study has been published.

Mechanistic Framework: Four Pathways Connecting MOTS-c to Sleep Quality

The following framework synthesizes published mechanisms into a clinical decision structure. It is original to HealthRX and has not appeared in prior literature in this form.

Pathway 1: AMPK-CK1ε-CRY1 circadian stabilization. MOTS-c activates AMPK. AMPK phosphorylates CK1ε, which alters CRY1 degradation rate. In states of AMPK underactivation (obesity, insulin resistance, aging), CRY1 is destabilized, shortening circadian period and fragmenting sleep. MOTS-c may restore CRY1 stability indirectly, re-lengthening circadian period toward the 24.2-hour human average. [3]

Pathway 2: Mitochondrial ROS reduction during SWS. Slow-wave sleep is the primary window for mitochondrial repair and ROS scavenging. Lee et al. Showed that MOTS-c reduces cellular ROS in adipose and muscle tissue. [1] Lower baseline ROS burden going into the sleep window may reduce the metabolic "load" that would otherwise trigger micro-arousals.

Pathway 3: FOXO1-mediated circadian gene expression. FOXO1 activation by MOTS-c may upregulate clock-controlled genes (CCGs) including PER1 and BMAL1 targets. This pathway is supported by Shimizu et al.'s FOXO-CLOCK binding data [9], but requires direct confirmation in the context of MOTS-c administration.

Pathway 4: Adipokine normalization and sleep-disordered breathing. Visceral adiposity, reduced by MOTS-c in animal models, increases leptin resistance and upper-airway inflammation. Both drive obstructive sleep apnea (OSA), which is the most common structural cause of disrupted sleep architecture. If MOTS-c reduces visceral fat, the downstream effect on pharyngeal anatomy could improve OSA-driven SWS disruption independent of any direct neurological action.

Clinical Considerations for Practitioners

Prescribers considering MOTS-c for patients with metabolic disease and co-occurring sleep complaints need to hold two truths at once: the mechanistic rationale for sleep effects is genuinely coherent, and the human RCT evidence base is, as of 2025, insufficient to make a definitive efficacy claim.

Patient Selection

Patients most likely to benefit from MOTS-c's metabolic effects, and by extension from any downstream sleep improvements, are those with insulin resistance (HOMA-IR above 2.0), age-related metabolic decline, or documented AMPK pathway dysfunction. Lean, young patients with primary insomnia of psychophysiological origin are not the right target for this peptide.

The AASM's position on pharmacological sleep therapy emphasizes matching mechanism to phenotype. [4] A patient with poor sleep rooted in metabolic syndrome, visceral obesity, and early-stage glucose intolerance fits the MOTS-c mechanistic profile far better than a patient with conditioned arousal or chronic stress.

Dosing Protocols in Use

Published protocols have used 2-10 mg subcutaneous dosing, one to five times per week. The Lee et al. Animal studies used weight-based dosing (15 mg/kg), which does not translate directly to human use. The Reynolds phase I work used flat 2 mg and 5 mg doses with acceptable safety profiles. [10] No published study has established a sleep-specific dose-response curve.

Timing of injection relative to sleep onset has not been studied. Given the circadian oscillation of endogenous MOTS-c (peak during rest phase in rodents), a late-afternoon or early-evening subcutaneous injection could theoretically align with endogenous secretion patterns. This is speculative and should be framed as such to patients.

Monitoring Recommendations

Baseline and follow-up testing for any patient receiving compounded MOTS-c for sleep-related indications should include fasting insulin, fasting glucose, HOMA-IR calculation, and, where practical, wrist actigraphy for 14 days pre- and post-initiation. Formal PSG is warranted in patients with suspected OSA regardless of MOTS-c use.

Practitioners should note that compounded MOTS-c is not FDA-approved and carries no standardized purity guarantee. The FDA's guidance on compounded peptides (2023 draft) explicitly places synthetic peptides under heightened scrutiny for purity, sterility, and potency verification. [12]

Drug Interactions

MOTS-c activates AMPK via pathways overlapping with metformin and berberine. Co-administration of MOTS-c with metformin 1,000-2,000 mg/day could produce additive AMPK activation. Whether that additive effect is beneficial or produces hypoglycemia risk requires individual assessment. No published interaction study exists.

What a Well-Designed Human Sleep Trial Would Need

The field needs a placebo-controlled, double-blind, parallel-group PSG study enrolling adults with metabolic syndrome (ATP III criteria) and objectively poor sleep (PSG-confirmed SWS below 15% of total sleep time or WASO above 45 minutes). The primary endpoint should be change in delta power spectral density (0.5-4 Hz) at 8 weeks. Secondary endpoints should include HOMA-IR, actigraphy sleep efficiency, REM density, and plasma MOTS-c AUC.

Sample size of N = 80 per arm (power = 0.80, alpha = 0.05) would detect a 15% improvement in delta power based on effect sizes seen with metabolic interventions in similar populations. [11]

Without that trial, every clinical statement about MOTS-c and sleep architecture remains at the level of mechanistic inference, not clinical proof.

Summary of Current Evidence Quality

| Outcome | Evidence Level | Source | |---|---|---| | Insulin sensitization (animal) | High (multiple replications) | Lee et al. 2015 [1] | | AMPK activation (in vitro, animal) | High | Lee et al. 2015 [1] | | Circadian oscillation of endogenous MOTS-c | Moderate (single rodent study) | Yen et al. 2020 [7] | | Human PK/safety | Low (N=12 phase I) | Reynolds et al. 2021 [10] | | Human sleep architecture (PSG) | None published | N/A | | Actigraphy sleep efficiency | Very low (preprint, N=24) | Yen group 2023 preprint |